Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 10/20 | 0.45 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | BLK | P51451 | 1/20 | 0.43 |
| ▸ | BMX | P51813 | 1/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484374 | 0.87 | ERBB2 (0.61) | ERBB2EGFRJAK2JAK3JAK1 | |
| SCHEMBL21516123 | 0.86 | PRMT5 (0.42) | KITERBB2EGFRBTKPRMT5 | |
| SCHEMBL21484381 | 0.85 | PRMT5 (0.47) | KITERBB2EGFREIF2AK2GSK3B | |
| SCHEMBL21516135 | 0.83 | KIT (0.43) | KITERBB2EGFREIF2AK2GSK3B | |
| SCHEMBL29539032 | 0.82 | EGFR (0.60) | KITERBB2EGFRJAK2JAK3 | |
| SCHEMBL21515828 | 0.82 | EGFR (0.60) | KITERBB2EGFRJAK2JAK3 | |
| SCHEMBL21484346 | 0.82 | EGFR (0.60) | KITERBB2EGFRJAK2JAK3 | |
| SCHEMBL21484373 | 0.82 | EGFR (0.47) | KITERBB2EGFRJAK2JAK3 | |
| SCHEMBL21484371 | 0.82 | EGFR (0.47) | KITERBB2EGFRJAK2JAK3 | |
| SCHEMBL29538561 | 0.82 | EGFR (0.47) | KITERBB2EGFRJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110072865-B | Pyrrolo-aromatic heterocyclic compounds, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | claimed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | claimed |
| US-11608334-B2 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2023-03-21 | — | — | US | disclosed |
| CN-110072865-B | Pyrrolo-aromatic heterocyclic compounds, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3556761-B1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RES AND DEVELOPMENT NIP (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3556761-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | The National Institutes Of Pharmaceutical Research (CN) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556761-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | The National Institutes Of Pharmaceutical Research (CN) | 2019-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608334-B2 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | BTK, SYK, ITK | KIT 440/4885ERBB2 317/4885EGFR 1705/4885 |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BTK, SYK, ITK | KIT 440/4885ERBB2 317/4885EGFR 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.